You are here

Yorvipath

MBX aims for $136M IPO to take potential rival to Ascendis' Yorvipath into phase 3

Fierce Biotech

Mon, 09/9/24 - 07:10 pm

MBX Biosciences

MBX files for IPO, seeking cash to take challenger to Ascendis' Yorvipath into phase 3

Fierce Biotech

Mon, 08/26/24 - 10:09 am

MBX Biosciences

Ascendis Pharma

A First for Hypoparathyroidism — Yorvipath (Palopegteriparatide) Earns FDA Nod

Xtalks

Thu, 08/22/24 - 09:51 pm

hypoparathyroidism

Ascendis Pharma

Ascendis scores hard-fought FDA nod for hormone replacement therapy Yorvipath

Fierce Pharma

Mon, 08/12/24 - 11:35 am

Ascendis Pharma

hypoparathyroidism